


01-14-02

1645

<div style="display: flex; justify-content: space-between;"> <div style="text-align: left;"> <p>PIPE</p> <p>JAN 09 2002</p> </div> <div style="text-align: center;"> <p>TRANSMITTAL LETTER</p> <p>(General - Patent Pending)</p> </div> </div>		<p>Docket No.</p> <p>021286/0276339</p>
<p>In Reply Application Of: Mikayama, et al.</p>		
<p>Serial No.</p> <p>09/844,684</p>	<p>Filing Date</p> <p>April 27, 2001</p>	<p>Examiner</p> <p>NYA</p>
<p>Group Art Unit</p> <p>1645</p>		
<p>Title: HUMAN ANTI-CD40 ANTIBODIES AND METHODS OF MAKING AND USING SAME</p> <div style="text-align: right; font-size: 1.2em; font-weight: bold;"> <p>RECEIVED</p> <p>JAN 18 2002</p> </div>		
<p style="text-align: right; font-weight: bold;">TECH CENTER 1600/2000</p> <p style="text-align: center;"><u>TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:</u></p> <p>Transmitted herewith is:</p> <p>1) Response to Notice to Comply; 2) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence; 3) Sequence Listing; 4) Statement Under 37 C.F.R. Section 1.821(f) and (g); 5) Diskette with Sequence Listing; 6) Certificate of Express Mailing; and 7) Reply postcard.</p> <p>in the above identified application.</p> <p><input checked="" type="checkbox"/> No additional fee is required.</p> <p><input type="checkbox"/> A check in the amount of _____ is attached.</p> <p><input type="checkbox"/> The Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.</p> <p style="margin-left: 20px;"> <input type="checkbox"/> Charge the amount of _____ <input type="checkbox"/> Credit any overpayment. <input type="checkbox"/> Charge any additional fee required. </p> <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="width: 40%;">  <p style="text-align: center;">Signature</p> <p>Robert M. Bedgood Reg. No. 43,488</p> </div> <div style="width: 50%;"> <p>Dated: January 9, 2002</p> <p>I hereby certify under 37 C.F.R. §1.10 that this document and corresponding transmittal documents are being deposited with the United States Postal Service as Express Mail Post Office on <u>January 9, 2002</u>, and is addressed to Commissioner for Patents, Washington, D.C. 20231.</p> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div style="width: 45%;"> <p><u>Linda Anders</u> Printed Name</p> <p><u>Linda Anders</u> Signature</p> </div> <div style="width: 45%;"> <p><u>EL 754037997 AS</u> Express Mail Label No.</p> </div> </div> </div> </div>		
<p>cc: SF Docketing</p>		



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mikayama, et al.

Examiner: NYA

Serial No.: 09/844,684

Group Art Unit: 1645

Filed: April 27, 2001

Docket: 021286/0276339

For: **HUMAN ANTI-CD40 ANTIBODIES AND METHODS OF MAKING AND USING SAME**

RESPONSE TO NOTICE TO COMPLY

Commissioner of Patents
Washington, D.C. 20231

Sir:


Responsive to the communication mailed December 12, 2001, Applicants submit herewith a paper copy and a computer readable form (diskette) of the sequence listing as required under 37 C.F.R. §1.821-§1.824 (a). The sequence listing is provided in ASCII text on the accompanying diskette. A copy of the notice to comply is attached to this response.

The paper copy and computer readable forms of the sequence listing are identical and do not add new matter. An executed statement under 37 C.F.R. §1.821 (f) and (g) to that effect is provided. Accordingly, please amend the specification by entering the enclosed sequence listing.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 1-9-02


Robert M. Bedgood
Reg. No. 43,488



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/844,684	04/27/2001	Toshifumi Mikayama	021286/027 6339

CONFIRMATION NO. 3283

FORMALITIES LETTER



OC000000007163930

Robert M. Bedgood
PILLSBURY WINTHROP LLP
50 Fremont Street
San Francisco, CA 94105

RECEIVED

DEC 12 2001

PILLSBURY WINTHROP LLP/SF

Date Mailed: 12/06/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- o This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/844,684	04/27/2001	Toshifumi Mikayama	021286/027 6339

CONFIRMATION NO. 3283

WITHDRAWAL NOTICE



OC000000007163925

Robert M. Bedgood
PILLSBURY WINTHROP LLP
50 Fremont Street
San Francisco, CA 94105

RECEIVED**DEC 12 2001**

PILLSBURY WINTHROP LLP/SF

Date Mailed: 12/06/2001

WITHDRAWAL OF PREVIOUSLY SENT NOTICE

The Notice mailed on 06/26/2001 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the corrected Notice. We apologize for any inconvenience this caused.

RECEIVED
JAN 18 2002
TECH CENTER 1600/2900

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY